Search Results - "Cohen, David J."

STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement by Carroll, John D., Mack, Michael J., Vemulapalli, Sreekanth, Herrmann, Howard C., Gleason, Thomas G., Hanzel, George, Deeb, G. Michael, Thourani, Vinod H., Cohen, David J., Desai, Nimesh, Kirtane, Ajay J., Fitzgerald, Susan, Michaels, Joan, Krohn, Carole, Masoudi, Frederick A., Brindis, Ralph G., Bavaria, Joseph E.

“…The STS-ACC TVT Registry (Society of Thoracic Surgeons–American College of Cardiology Transcatheter Valve Therapy Registry) from 2011 to 2019 has collected…”
Get full text

Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research by Généreux, Philippe, Piazza, Nicolo, Alu, Maria C, Nazif, Tamim, Hahn, Rebecca T, Pibarot, Philippe, Bax, Jeroen J, Leipsic, Jonathon A, Blanke, Philipp, Blackstone, Eugene H, Finn, Matthew T, Kapadia, Samir, Linke, Axel, Mack, Michael J, Makkar, Raj, Mehran, Roxana, Popma, Jeffrey J, Reardon, Michael, Rodes-Cabau, Josep, Van Mieghem, Nicolas M, Webb, John G, Cohen, David J, Leon, Martin B

“…Abstract Aims  The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize…”
Get full text

COVID‐19 in solid organ transplant recipients: Initial report from the US epicenter by Pereira, Marcus R., Mohan, Sumit, Cohen, David J., Husain, Syed A., Dube, Geoffrey K., Ratner, Lloyd E., Arcasoy, Selim, Aversa, Meghan M., Benvenuto, Luke J., Dadhania, Darshana M., Kapur, Sandip, Dove, Lorna M., Brown, Robert S., Rosenblatt, Russell E., Samstein, Benjamin, Uriel, Nir, Farr, Maryjane A., Satlin, Michael, Small, Catherine B., Walsh, Thomas J., Kodiyanplakkal, Rosy P., Miko, Benjamin A., Aaron, Justin G., Tsapepas, Demetra S., Emond, Jean C., Verna, Elizabeth C.

“…Solid organ transplant recipients may be at a high risk for SARS‐CoV‐2 infection and poor associated outcomes. We herein report our initial experience with…”
Get full text

Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement by Makkar, Raj R, Thourani, Vinod H, Mack, Michael J, Kodali, Susheel K, Kapadia, Samir, Webb, John G, Yoon, Sung-Han, Trento, Alfredo, Svensson, Lars G, Herrmann, Howard C, Szeto, Wilson Y, Miller, D. Craig, Satler, Lowell, Cohen, David J, Dewey, Todd M, Babaliaros, Vasilis, Williams, Mathew R, Kereiakes, Dean J, Zajarias, Alan, Greason, Kevin L, Whisenant, Brian K, Hodson, Robert W, Brown, David L, Fearon, William F, Russo, Mark J, Pibarot, Philippe, Hahn, Rebecca T, Jaber, Wael A, Rogers, Erin, Xu, Ke, Wheeler, Jaime, Alu, Maria C, Smith, Craig R, Leon, Martin B

“…Intermediate-risk patients with aortic stenosis were randomly assigned to undergo either transcatheter or surgical aortic-valve replacement. At 5 years, there…”
Get full text

Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years by Mack, Michael J, Leon, Martin B, Thourani, Vinod H, Pibarot, Philippe, Hahn, Rebecca T, Genereux, Philippe, Kodali, Susheel K, Kapadia, Samir R, Cohen, David J, Pocock, Stuart J, Lu, Michael, White, Roseann, Szerlip, Molly, Ternacle, Julien, Malaisrie, S Chris, Herrmann, Howard C, Szeto, Wilson Y, Russo, Mark J, Babaliaros, Vasilis, Smith, Craig R, Blanke, Philipp, Webb, John G, Makkar, Raj

“…A previous analysis in this trial showed that among patients with severe, symptomatic aortic stenosis who were at low surgical risk, the rate of the composite…”
Get full text

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention by Yeh, Robert W, Secemsky, Eric A, Kereiakes, Dean J, Normand, Sharon-Lise T, Gershlick, Anthony H, Cohen, David J, Spertus, John A, Steg, Philippe Gabriel, Cutlip, Donald E, Rinaldi, Michael J, Camenzind, Edoardo, Wijns, William, Apruzzese, Patricia K, Song, Yang, Massaro, Joseph M, Mauri, Laura

“…IMPORTANCE: Dual antiplatelet therapy after percutaneous coronary intervention (PCI) reduces ischemia but increases bleeding. OBJECTIVE: To develop a clinical…”
Get full text

Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy by Kazi, Dhruv S., Bellows, Brandon K., Baron, Suzanne J., Shen, Changyu, Cohen, David J., Spertus, John A., Yeh, Robert W., Arnold, Suzanne V., Sperry, Brett W., Maurer, Mathew S., Shah, Sanjiv J.

“…BACKGROUND:In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline…”
Get full text

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients by Leon, Martin B, Smith, Craig R, Mack, Michael J, Makkar, Raj R, Svensson, Lars G, Kodali, Susheel K, Thourani, Vinod H, Tuzcu, E. Murat, Miller, D. Craig, Herrmann, Howard C, Doshi, Darshan, Cohen, David J, Pichard, Augusto D, Kapadia, Samir, Dewey, Todd, Babaliaros, Vasilis, Szeto, Wilson Y, Williams, Mathew R, Kereiakes, Dean, Zajarias, Alan, Greason, Kevin L, Whisenant, Brian K, Hodson, Robert W, Moses, Jeffrey W, Trento, Alfredo, Brown, David L, Fearon, William F, Pibarot, Philippe, Hahn, Rebecca T, Jaber, Wael A, Anderson, William N, Alu, Maria C, Webb, John G

“…In a randomized trial involving more than 2000 patients, transcatheter aortic-valve replacement was noninferior to surgical replacement in the primary end…”
Get full text

Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation by Stone, Gregg W., Abraham, William T., Lindenfeld, JoAnn, Kar, Saibal, Grayburn, Paul A., Lim, D. Scott, Mishell, Jacob M., Whisenant, Brian, Rinaldi, Michael, Kapadia, Samir R., Rajagopal, Vivek, Sarembock, Ian J., Brieke, Andreas, Marx, Steven O., Cohen, David J., Asch, Federico M., Mack, Michael J.

“…Transcatheter repair of secondary mitral regurgitation was associated with a lower rate of hospitalization for heart failure and lower all-cause mortality than…”
Get full text

Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis by Vedantham, Suresh, Goldhaber, Samuel Z, Julian, Jim A, Kahn, Susan R, Jaff, Michael R, Cohen, David J, Magnuson, Elizabeth, Razavi, Mahmood K, Comerota, Anthony J, Gornik, Heather L, Murphy, Timothy P, Lewis, Lawrence, Duncan, James R, Nieters, Patricia, Derfler, Mary C, Filion, Marc, Gu, Chu-Shu, Kee, Stephen, Schneider, Joseph, Saad, Nael, Blinder, Morey, Moll, Stephan, Sacks, David, Lin, Judith, Rundback, John, Garcia, Mark, Razdan, Rahul, VanderWoude, Eric, Marques, Vasco, Kearon, Clive

“…Patients with proximal deep-vein thrombosis were assigned to undergo anticoagulation either alone or combined with pharmacomechanical thrombolysis. After 6 to…”
Get full text

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk by Leon, Martin B., Mack, Michael J., Hahn, Rebecca T., Thourani, Vinod H., Makkar, Raj, Kodali, Susheel K., Alu, Maria C., Madhavan, Mahesh V., Chau, Katherine H., Russo, Mark, Kapadia, Samir R., Malaisrie, S. Chris, Cohen, David J., Blanke, Philipp, Leipsic, Jonathon A., Williams, Mathew R., McCabe, James M., Brown, David L., Babaliaros, Vasilis, Goldman, Scott, Herrmann, Howard C., Szeto, Wilson Y., Genereux, Philippe, Pershad, Ashish, Lu, Michael, Webb, John G., Smith, Craig R., Pibarot, Philippe

“…In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low…”
Get full text

Incidence, Predictors, and Prognostic Impact of Late Bleeding Complications After Transcatheter Aortic Valve Replacement by Généreux, Philippe, MD, Cohen, David J., MD, MSc, Mack, Michael, MD, Rodes-Cabau, Josep, MD, Yadav, Mayank, MD, Xu, Ke, PhD, Parvataneni, Rupa, MS, Hahn, Rebecca, MD, Kodali, Susheel K., MD, Webb, John G., MD, Leon, Martin B., MD

“…Abstract Background The incidence and prognostic impact of late bleeding complications after transcatheter aortic valve replacement (TAVR) are unknown…”
Get full text

Staging classification of aortic stenosis based on the extent of cardiac damage by Généreux, Philippe, Pibarot, Philippe, Redfors, Björn, Mack, Michael J, Makkar, Raj R, Jaber, Wael A, Svensson, Lars G, Kapadia, Samir, Tuzcu, E Murat, Thourani, Vinod H, Babaliaros, Vasilis, Herrmann, Howard C, Szeto, Wilson Y, Cohen, David J, Lindman, Brian R, McAndrew, Thomas, Alu, Maria C, Douglas, Pamela S, Hahn, Rebecca T, Kodali, Susheel K, Smith, Craig R, Miller, D Craig, Webb, John G, Leon, Martin B

“…In patients with aortic stenosis (AS), risk stratification for aortic valve replacement (AVR) relies mainly on valve-related factors, symptoms and…”
Get full text

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents by Mauri, Laura, Kereiakes, Dean J, Yeh, Robert W, Driscoll-Shempp, Priscilla, Cutlip, Donald E, Steg, P. Gabriel, Normand, Sharon-Lise T, Braunwald, Eugene, Wiviott, Stephen D, Cohen, David J, Holmes, David R, Krucoff, Mitchell W, Hermiller, James, Dauerman, Harold L, Simon, Daniel I, Kandzari, David E, Garratt, Kirk N, Lee, David P, Pow, Thomas K, Ver Lee, Peter, Rinaldi, Michael J, Massaro, Joseph M

“…Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin…”
Get full text

Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement by Arnold, Suzanne V., MD, MHA, Afilalo, Jonathan, MD, MSc, Spertus, John A., MD, MPH, Tang, Yuanyuan, PhD, Baron, Suzanne J., MD, MSc, Jones, Philip G., MS, Reardon, Michael J., MD, Yakubov, Steven J., MD, Adams, David H., MD, Cohen, David J., MD, MSc

“…Abstract Background A series of models have been developed to identify patients at high risk for poor outcomes after transcatheter aortic valve replacement…”
Get full text

Relation of Frailty to Outcomes After Transcatheter Aortic Valve Replacement (from the PARTNER Trial) by Green, Philip, MD, Arnold, Suzanne V., MD, MHA, Cohen, David J., MD, MSc, Kirtane, Ajay J., MD, SM, Kodali, Susheel K., MD, Brown, David L., MD, Rihal, Charanjit S., MD, Xu, Ke, PhD, Lei, Yang, PhD, Hawkey, Marian C., RN, Kim, Rebeca J., BA, Alu, Maria C., MM, Leon, Martin B., MD, Mack, Michael J., MD

“…Transcatheter aortic valve replacement (TAVR) is an effective treatment for severe symptomatic aortic stenosis (AS) in patients who are inoperable or at high…”
Get full text

Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis by Cooper, Christopher J, Murphy, Timothy P, Cutlip, Donald E, Jamerson, Kenneth, Henrich, William, Reid, Diane M, Cohen, David J, Matsumoto, Alan H, Steffes, Michael, Jaff, Michael R, Prince, Martin R, Lewis, Eldrin F, Tuttle, Katherine R, Shapiro, Joseph I, Rundback, John H, Massaro, Joseph M, D'Agostino, Ralph B, Dworkin, Lance D

“…In this trial, 947 patients with renal-artery stenosis were assigned to renal-artery stenting or medical therapy. At a median of 43 months, there was no…”
Get full text

Bioprosthetic Valve Fracture to Facilitate Transcatheter Valve-in-Valve Implantation by Allen, Keith B., Chhatriwalla, Adnan K., Cohen, David J., Saxon, John T., Aggarwal, Sanjeev, Hart, Anthony, Baron, Suzanne, Davis, J. Russell, Pak, Alex F., Dvir, Danny, Borkon, A. Michael

“…Valve-in-valve transcatheter aortic valve replacement is less effective in small surgical bioprostheses. We evaluated the feasibility of bioprosthetic valve…”
Get full text

Additively manufactured 3D porous Ti-6Al-4V constructs mimic trabecular bone structure and regulate osteoblast proliferation, differentiation and local factor production in a porosity and surface roughness dependent manner by Cheng, Alice, Humayun, Aiza, Cohen, David J, Boyan, Barbara D, Schwartz, Zvi

“…Additive manufacturing by laser sintering is able to produce high resolution metal constructs for orthopedic and dental implants. In this study, we used a…”
Get more information

Interpreting the Results of Cost-Effectiveness Studies by Cohen, David J., MD, MSc, FACC, Reynolds, Matthew R., MD, MSc, FACC

“…In developed nations, health care spending is an increasingly important economic and political issue. The discipline of cost-effectiveness (CE) analysis has…”
Get full text